WATCH
They make surgical robots. Their install base is growing, but their PE always been too high. They might change because shares have come off. Don't buy, but watch.
biotechnology / pharmaceutical

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
HOLD
He likes it and will stick by it, but the market isn't fond of this sector.
biotechnology / pharmaceutical
TOP PICK
Leader in robotic surgery. Relatively early days in this space, and ISRG has a massive head start. Both JNJ and MDT are trying to enter this market and having trouble. Recurring revenue model drives financial performance. Less invasive, new product for diagnosing lung tumours. Expensive PE, but highly profitable. He expects 10-15% growth of topline revenue for next decade. No dividend. (Analysts’ price target is $250.34)
biotechnology / pharmaceutical
PARTIAL BUY
Leader in robotic surgeries. More volatility due to concentration in that area. Still trades at 36x earnings. Solid growth franchise. Could be subject to M&A. He prefers a more diversified company. You could ladder into it.
biotechnology / pharmaceutical
BUY
Add to position? Yes, as Covid peaks, this stock will go back up though not much beyond its highs. This was hurt by lockdowns which halted surgeries.
biotechnology / pharmaceutical
STRONG BUY
Very well positioned in robotics surgery, the leader by far. Go-to name. More and more procedures will be performed by robots. Very bullish.
biotechnology / pharmaceutical
BUY
Great management and growth. He's a big fan.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Aug 24/20, Up 18%) Leader in robotic surgery. Penetration is only about 5% right now, so lots of room to grow. Expensive, but very sure growth. Can hold it forever.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Apr 17/20, Up 65%) Doctors are trained to use their system so competitors find it hard to get into the market. They are starting to reduce prices on some of their tools ahead of the coming competition. He will hold it for the foreseeable future.
biotechnology / pharmaceutical
BUY
Allan Tong’s Discover Picks I recommended this last August. As we face the reopening and eventual recovery, elective surgeries will bounce back and there will be a huge backlog to process. This backlog spells a boom for any company directly tied to surgeries. That’s short term. A longer-term tailwind for ISRG stock is the continued adoption of robotic surgery and this is where the automation stock shines bright. Robotic surgeries increased from 1.8% of all operations in 2012 to 15.1% in 2018. Read 3 Underestimated Automation Stocks for our full analysis.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jan 02/20, Up 27%) A great long-term play on robotically assisted surgery, a leader in this area. It's an expensive growth stock, but the outlook is so strong it's worth it. There's lots of room globally for surgery to adopt this technology.
biotechnology / pharmaceutical
BUY
Fractional shares to buy instead of playing the short squeeze of GameStop, AMC, etc. They make precision surgical machines which amazes him. Promising.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Aug 19/19, Up 49%) A leader in robotic surgery. It provides a better surgical experience with more precise surgeries. The long-term story is that right now, robotic surgery accounts for 4% of surgeries right now. They have a huge head start in this domain and have great cashflow.
biotechnology / pharmaceutical
BUY

JNJ JNJ is trying to respond to the rise of robotic surgery by Intuitive Surgical, which he prefers. This take time and research for JNJ, which means Intuitive will still be ahead of JNJ.

biotechnology / pharmaceutical
BUY

Allan Tong’s Discover Picks Both Jamie Murray and Bruce Murray (unrelated) see strong long-term growth ahead for the company as more surgeons adapt robotic devices. ISRG's market share is currently only 4%, but Bruce Murray expects the company to grow 50% next year and 20% after that. However, investors have already caught onto this stock and ISRG stock has almost doubled from the March 23 bottom; it has passed its $655 price target and is flirting with $700. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.

biotechnology / pharmaceutical
Showing 1 to 15 of 26 entries

Intuitive Surgical Inc.(ISRG-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Intuitive Surgical Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Intuitive Surgical Inc.(ISRG-Q) Frequently Asked Questions

What is Intuitive Surgical Inc. stock symbol?

Intuitive Surgical Inc. is a American stock, trading under the symbol ISRG-Q on the NASDAQ (ISRG). It is usually referred to as NASDAQ:ISRG or ISRG-Q

Is Intuitive Surgical Inc. a buy or a sell?

In the last year, 4 stock analysts published opinions about ISRG-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Intuitive Surgical Inc..

Is Intuitive Surgical Inc. a good investment or a top pick?

Intuitive Surgical Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Intuitive Surgical Inc..

Why is Intuitive Surgical Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Intuitive Surgical Inc. worth watching?

4 stock analysts on Stockchase covered Intuitive Surgical Inc. In the last year. It is a trending stock that is worth watching.

What is Intuitive Surgical Inc. stock price?

On 2022-11-28, Intuitive Surgical Inc. (ISRG-Q) stock closed at a price of $265.42.